Lexaria Bioscience - Warrants (11/01/2026) Profit Margin

Lexaria Bioscience - Warrants (11/01/2026) (LEXXW) currently reports a profit margin of -3985.58% as of May 2026. That compares with -1849.39% in the prior-year period — down 115.5% year over year. That is below the Healthcare sector average of 19.13%. Use the charts on this page to explore Lexaria Bioscience - Warrants (11/01/2026)'s profit margin history and peer comparisons.

Lexaria Bioscience - Warrants (11/01/2026)'s profit margin decreased from -1849.39% to -3985.58% — a 115.5% year-over-year decrease (period ending May 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lexaria Bioscience - Warrants (11/01/2026)'s profit margin of -3985.58% is lower than the Healthcare sector average of 19.13%. That is roughly 20932.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Lexaria Bioscience - Warrants (11/01/2026)'s current -3985.58% should be judged against Healthcare norms (sector average: 19.13%) and against LEXXW's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -3985.58%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 19.13%. From there, open related valuation or income-statement pages for Lexaria Bioscience - Warrants (11/01/2026), and consider following LEXXW for alerts when major investors trade the stock.